The aim of this study was to explore the feasibility and efficacy of a non-invasive quantitative imaging evaluation model to assess the lymphatic metastasis of breast cancer based on a radiomics signature constructed using conventional T1-weighted image (T1WI) enhanced MRI and molecular biomarkers.
Patients with breast cancer diagnosed
In all, 100 patients were enrolled in this study, including 45 with non-lymph node (LN) metastasis and 55 with LN metastasis. A total of 1,051 texture feature parameters were extracted, and LASSO was used to reduce the dimensionality of the radiomics features. The log(λ) was set to 0.002786, and 19 parameters were retained for the construction of the radiomics tag Rad-score. ROC was used to evaluate the diagnostic efficiency of Rad-score: the area under the ROC curve (AUC) of the Rad-score for identifying non-lymphatic and lymphatic metastases was 0.891 in the training cohort and 0.744 in the validation cohort. With the incorporation of tumor molecular markers, the AUCs of the training cohort and validation cohort of the nomogram were 0.936 and 0.793, respectively, which were notably higher than the AUCs of the clinical parameters in the training and validation cohorts (0.719 and 0.588, respectively).
The combined model constructed using the Rad-score and molecular biomarkers can be used as an effective non-invasive method to assess LN metastasis of breast cancer. Furthermore, it can be used to quantitatively evaluate the risk of breast cancer LN metastasis before surgery.